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Abstract
Background: In March 2008, the D:A:D study published results demonstrating an increased risk of myocardial
infarction (MI) for patients on abacavir (ABC). We describe changes to the use of ABC since this date, and
investigate changes to the association between ABC and MI with subsequent follow-up.
Methods: A total of 49,717 D:A:D participants were followed from study entry until the first of an MI, death, 1
February 2013 or 6 months after last visit. Associations between a person’s 10-year cardiovascular disease (CVD) risk
and the likelihood of initiating or discontinuing ABC were assessed using multivariable logistic/Poisson regression.
Poisson regression was used to assess the association between current ABC use and MI risk, adjusting for potential
confounders, and a test of interaction was performed to assess whether the association had changed in the post-
March 2008 period.
Results: Use of ABC increased from 10 % of the cohort in 2000 to 20 % in 2008, before stabilising at 18–19 %.
Increases in use pre-March 2008, and subsequent decreases, were greatest in those at moderate and high CVD
risk. Post-March 2008, those on ABC at moderate/high CVD risk were more likely to discontinue ABC than those
at low/unknown CVD risk, regardless of viral load (≤1,000 copies/ml: relative rate 1.49 [95 % confidence interval
1.34–1.65]; >1,000 copies/ml: 1.23 [1.02–1.48]); no such associations were seen pre-March 2008. There was some
evidence that antiretroviral therapy (ART)-naïve persons at moderate/high CVD risk post-March 2008 were less likely
to initiate ABC than those at low/unknown CVD risk (odds ratio 0.74 [0.48–1.13]). By 1 February 2013, 941 MI events
had occurred in 367,559 person-years. Current ABC use was associated with a 98 % increase in MI rate (RR 1.98
[1.72–2.29]) with no difference in the pre- (1.97 [1.68–2.33]) or post- (1.97 [1.43–2.72]) March 2008 periods
(interaction P = 0.74).
Conclusions: Despite a reduction in the channelling of ABC for patients at higher CVD risk since 2008, we continue
to observe an association between ABC use and MI risk. Whilst confounding cannot be fully ruled out, this further
diminishes channelling bias as an explanation for our findings.
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Background
In March 2008, the Data Collection on Adverse Events
of Anti-HIV Drugs (D:A:D) study presented findings at
the 15th Conference on Retroviruses and Opportunistic
Infections in Boston demonstrating a 90 % increase in
the risk of myocardial infarction (MI) in HIV-positive in-
dividuals receiving antiretroviral therapy (ART) regimens
that included abacavir (ABC) [1]; these findings were
published in The Lancet in April 2008 [2]. Subsequent
attempts by other studies to replicate these findings have
been inconsistent, with some studies reporting a similar
association [3–9] and others not [10–12]. Other studies
have reported that a significant association in univariable
analyses disappeared after adjustment for renal dysfunc-
tion or use of recreational drugs [13, 14]. Published
meta-analyses on the topic have also been inconsistent
[15, 16]. Studies have explored mechanisms that could
explain this association, for example, those which sug-
gest that an increased risk of MI in patients receiving
ABC may be a result of the propensity of the drug to in-
duce platelet hyperreactivity [17–19].
One of the limitations of observational studies is the
potential for confounding to introduce bias in any com-
parison of outcomes among those receiving different
ART drugs. In the case of ABC, confounding was of real
concern, as the drug was traditionally preferentially pre-
scribed to those at higher underlying risk of cardiovascu-
lar disease (CVD), where clinicians had avoided the use
of other nucleoside reverse transcriptase inhibitors
(NRTIs) that were known to have adverse lipid effects
[20]. Thus, individuals receiving ABC before our find-
ings were presented in 2008 were expected to have a
higher underlying risk of CVD as a result of this ‘chan-
nelling bias’. The initial D:A:D analyses had adjusted for
all factors that were thought to potentially confound any
association between ABC use and MI risk, including age,
sex, HIV mode of acquisition, ethnicity, calendar year,
cohort, smoking status, family and personal history of
CVD, body mass index (BMI), and exposure to other
ART drugs [1, 2]. Subsequent analyses additionally in-
cluded adjustment for renal dysfunction [21], a factor
also known to be associated with a higher underlying
CVD risk, with similar findings. In addition, we provided
further arguments against confounding as an explan-
ation, notably that the association with MI appeared to
be reversible on discontinuation of the drug, and that
there was no similar association with tenofovir (another
NRTI where channelling might be expected to act in the
same direction). Nevertheless, there remained concern
that it was not possible to fully account for the channel-
ling of high CVD risk patients onto ABC, meaning that
residual confounding may have remained.
Since the findings in the D:A:D publication of 2008 of
a possible elevated risk of MI when ABC is prescribed in
persons with already elevated underlying CVD risk,
there have been subsequent changes to the package in-
sert for ABC, and several changes to international guide-
lines for use of the drug as part of ART treatment of
HIV-positive individuals [22, 23]. As a result, it is likely
that prescribing patterns of ABC have changed, particu-
larly for those at higher risk of CVD [24], meaning that
the channelling of patients with high CVD risk onto
ABC is reduced, absent or even reversed. In this paper,
we describe changes in the use of ABC among partici-
pants in the D:A:D study since publication of the find-
ings in March 2008, and investigate whether the
association between ABC and MI remains present in
data collected after this time, when ABC would be less
likely to be prescribed to those at high CVD risk than
before 2008. In this way, our report describes an ex-
ample of how the various aspects of science have con-
tributed to a better understanding of a potential causal
association after a safety signal was first identified.
Methods
Study design
The D:A:D study is an observational study of >49,000
HIV-1-positive patients from 11 cohorts from Europe,
Australia and the United States [25]. All participants
were under active follow-up in their cohorts at the time
of enrolment in the D:A:D study. The primary study aim
is to investigate associations between the use of ART
drugs and the risk of CVD and other major disease
events. Data are collected prospectively during routine
clinic visits; the standardised dataset includes informa-
tion on socio-demographic factors (including ethnicity
which is captured as part of individual cohort data col-
lection processes, where permitted), AIDS events and
deaths, known risk factors for CVD, laboratory markers
for monitoring HIV (including CD4 count and HIV
RNA) and CVD, ART and treatments that influence
CVD risk. Enrolment in the D:A:D study took place in
three phases: enrolment cohort I (enrolment from
1999–2000); enrolment cohort II (added in 2004); and
enrolment cohort III (added in 2009).
Information on all incident cases of MI are reported to
the study coordinating centre via a study event form
which captures detailed information about the event and
related circumstances. Study personnel (at the coordin-
ating centre and at local sites) receive extensive training
in the identification of events and completion of the
event form. Once the event form has been received, each
event is validated (with dialogue between the coordinat-
ing centre and local site to clarify any discrepancies or
queries) and coded using criteria applied in the WHO
MONICA Project [26]. Validation and coding is per-
formed blind to information on the patient’s ART status.
Reported MIs are classified as definite, possible and
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unclassifiable; events with insufficient evidence to verify
that the event was, indeed, an MI were rejected. Stan-
dardised criteria for classification included relevant
symptoms, relevant increase and decline in cardiac en-
zymes, ischaemic changes in electrocardiographic (ECG)
readings and, in cases of death, autopsy results, if avail-
able. A sample of all MI events further undergoes add-
itional checks by an external independent cardiologist,
and a sample of patient records are verified at source to
ensure that events are not missed. Non-fatal MIs not as-
sociated with clinical symptoms were not considered as
events.
Ethics, consent and permissions
All participating cohorts followed local national guide-
lines/regulations regarding patient consent and/or eth-
ical review.
Statistical methods
The demographic and clinical characteristics of individ-
uals in the D:A:D study under follow-up on 1 January
each year were summarised, as was the proportion of
follow-up time in each year that was contributed by in-
dividuals receiving ABC (overall and after stratification
by the individual’s 10-year CVD risk). Each individual’s
10-year CVD risk was calculated using the Framingham
equation and was classified as low (<10 %), moderate
(10–20 %), high (>20 %) or unknown. Note that al-
though the D:A:D study has also published a CVD risk
score [27], this was not in widespread use over the
period of interest and so we used the Framingham score
for stratification.
To investigate changes in the initiation of ABC as part
of first-line ART regimens, we identified all ART-naïve
individuals who initiated ART for the first time during
prospective follow-up. Logistic regression models were
used to assess associations of the calendar period (pre-/
post-1 March 2008) and 10-year CVD risk (low/un-
known or moderate/high) with whether the initial ART
regimen included ABC or not. Analyses included adjust-
ment for the following potential confounders: gender,
mode of HIV acquisition, ethnicity, age, BMI, family
(first degree relative) or personal history of an MI, and
the individual’s CD4 count at the time of initiation of
ART. To test whether the association between CVD risk
and initiation of ABC had changed in the post-2008 era,
tests of interaction were performed between calendar
period and 10-year CVD risk group. Stratified analyses
were performed to obtain estimates of the odds ratio for
initiation of ABC according to CVD risk in the two cal-
endar periods separately.
To investigate changes in the likelihood of discontinu-
ing ABC in the post-March 2008 period, patients receiv-
ing an ABC-containing regimen were followed from the
time of initiation of that regimen until discontinuation
of ABC, or the earliest of death, 1 February 2013 or
6 months after the individual’s last clinic visit (the cen-
soring date for all analyses). Poisson regression was used
to describe associations between the calendar period,
CVD risk group and the rate of ABC discontinuation,
with adjustment for potential confounders as described
above. Interaction tests and stratified analyses were again
performed to assess whether associations between CVD
risk and ABC discontinuation had changed over time.
To reflect the fact that factors predicting ABC discon-
tinuation may differ in the context of a suppressed or
non-suppressed viral load, analyses were performed sep-
arately for follow-up time spent with a suppressed/low
(≤1,000 copies/ml) or non-suppressed (>1,000 copies/
ml) viral load; the cut-off of 1,000 copies/ml reflects the
fact that in many clinical situations, clinicians may
address adherence concerns first in individuals with de-
tectable but low viral loads, before considering changes
in ART.
Finally, to investigate whether the reported association
between current use of ABC and MI risk has changed in
the post-March 2008 period, we performed a similar
analysis to that reported in the 2008 paper [2]. Specific-
ally, individuals were followed from study entry to the
time of an MI, with censoring as described above. As in
previous analyses of the dataset, each individual’s follow-
up was split into a series of consecutive 1-month periods
and his/her clinical, immunologic and virologic status at
the start of each period was established. Poisson regres-
sion was then used to assess the association between
current use of ABC (with a 6-month grace period to
allow for recent discontinuation) and MI risk, adjusting
for use of other ART drugs and known confounders
(fixed covariates: gender, mode of HIV acquisition, ethni-
city, participating clinical cohort; time-updated covari-
ates: age, smoking status, family history of CVD,
previous CVD event, BMI, cumulative exposure to the
main protease inhibitors and non-NRTIs, and cumula-
tive and current exposure to other NRTIs). These ana-
lyses did not adjust for factors thought to potentially lie
on the causal pathway between ABC use and MI risk,
due to the possibility of the introduction of bias to such
analyses. Of note, reflecting our previous findings and
the state of evidence surrounding the possible mechan-
ism of any association with ABC, which would be con-
sistent with a short-lived on/off effect, only current
exposure to ABC was considered in analyses. Statistical
tests of interaction were again performed to test whether
the association between ABC and MI rate had changed
in the post-March 2008 period. Subsequent sensitivity
analyses additionally adjusted for factors that might po-
tentially fall on the causal pathway between use of ABC
and MI risk, including diabetes mellitus, total and high-
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density lipoprotein cholesterol (HDL-C), triglycerides,
systolic and diastolic blood pressure, receipt of anti-
hypertensive drugs or ACE inhibitors, blood glucose,
Framingham score, weight loss or gain, and renal func-
tion (expressed using the latest creatinine measurement,
categorised into eight equally sized groups with a further
category for those with missing creatinine measure-
ments), all as time-updated covariates. Further sensitivity
analyses incorporated the latest creatinine measurement
in its continuous form, and also expressed renal function
using the estimated glomerular filtration rate (either as a
categorical or continuous covariate).
All analyses were performed using SAS version 9.13
(SAS Institute, Cary, NC, USA).
Results
Changes in the use of ABC over time
The D:A:D cohort currently comprises 49,717 individ-
uals, of whom 73.8 % are male. Median age at cohort
entry was 38 (interquartile range 32–44) years. The ma-
jority of participants were infected with HIV through
sex between men (44.1 %) or sex between men and
women (32.6 %), with 15.3 % infected via injection drug
use and 8.0 % through other or unknown routes. Around
half of the cohort (50.6 %) is white, with 6.8 % of black
African origin and 2.9 % of other ethnicities; information
on ethnicity is unknown for 36.7 % of the cohort, largely
because the collection of information on ethnicity is pro-
hibited in several participating countries.
By 1 February 2013, individuals in the cohort had ac-
crued a total of 367,559 person-years (PYRS) of follow-
up (median 7.0, interquartile range 4.4–11.1 years),
210,250 of which had been accrued before 1 March 2008
and 157,309 after 1 March 2008. The changing charac-
teristics of the cohort over time are shown in Table 1; as
expected, there has been a gradual increase in the age of
the cohort over time and a gradual increase in the pro-
portion with an AIDS event. Among those with known
smoking status, the proportion of current smokers has
dropped somewhat since 2005. Despite the ageing of the
cohort, there have been positive changes in the propor-
tion with dyslipidaemia and, in line with increased use of
effective combination ART (cART), increases in the me-
dian CD4 count and decreases in the median HIV RNA
level over time.
Use of ABC among cohort participants increased from
10.4 % of those under follow-up in 2000 to 19.7 % of
those under follow-up in 2008. Since then, the rate has
stabilised at around 18–19 % (Fig. 1). After stratification
by 10-year CVD risk, increases in use of ABC pre-
March 2008, and subsequent decreases, were seen to be
greatest in those at moderate and high CVD risk. For ex-
ample, among those at moderate CVD risk in each year,
use of ABC increased from 14.9 % in 2000 to 25.4 % in
2008 before dropping 21.2 % in 2012. Similarly, among
those at high CVD risk, use of ABC was 17.5 %, 26.6 %
and 21.7 % in these three years, respectively.
Treatment initiations (Table 2i)
Overall, there were 14,765 new initiations of ART
among ART-naïve patients, of which 1,721 (11.7 %) in-
volved initiation of ABC. Among the 9,861 ART initia-
tions that occurred prior to March 2008, 1,362 (13.8 %)
involved ABC, compared to 359 of 4,904 (7.3 %) ART
initiations occurring after March 2008. In the pre-March
2008 era, those with a moderate or high CVD risk were
somewhat more likely to initiate ABC as part of first-line
regimens than those with low or unknown CVD risk
(adjusted odds ratio 1.14 [95 % confidence interval (CI)
0.90–1.44]). In contrast, in the post-March 2008 period,
those with moderate or high CVD risk were less likely to
initiate first-line regimens that included ABC (0.74
[0.48–1.13]). A statistical interaction test demonstrated
that this change was statistically significant (P = 0.0007).
Treatment discontinuations (Table 2ii)
Among those with a suppressed viral load, there were
4,890 ABC discontinuations over a total follow-up of
42,481 PYRS (rate 11.5/100 PYRS). Prior to March 2008
there had been a total of 2,607 ABC discontinuations
over 21,971 PYRS (11.9/100 PYRS) and this dropped to
2,283 discontinuations over 20,510 PYRS (11.1/100
PYRS) post-March 2008. These patterns differed, how-
ever, by 10-year CVD risk score, with a decrease in dis-
continuation rate from 12.4 to 10.1/100 PYRS in those
with low or unknown CVD risk score, but an increase in
discontinuation rates from 10.3 to 13.4/100 PYRS in
those with moderate or high CVD risk. Compared to
those with a low or unknown CVD risk, those with a
moderate or high CVD risk had a similar rate of switch-
ing in the pre-2008 era (adjusted rate ratio (aRR) 1.04
[0.93–1.16]) but in the post-March 2008 era those at
moderate or high CVD risk were significantly more
likely to discontinue ABC (aRR 1.49 [1.34–1.65], P value
for interaction = 0.0001).
Among those with a non-suppressed viral load, there
were 4,486 ABC discontinuations over a total follow-up
of 13,025 PYRS (rate 33.4/100 PYRS). Prior to March
2008 there had been a total of 3,628 ABC discontinua-
tions over 9,808 PYRS (37.0/100 PYRS) and this dropped
to 858 discontinuations over 3,217 PYRS (26.7/100
PYRS) post-March 2008. Whilst overall there was a de-
crease in discontinuation rates over the two periods, re-
gardless of the individual’s underlying CVD risk score,
the relative decrease in discontinuation was lower in
those with a moderate or high underlying risk. Thus,
whereas in the pre-March 2008 era, the results sug-
gested that those with low/unknown CVD risk had a
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Table 1 Demographic and cardiovascular risk characteristics of the D:A:D cohort over time. The information shown in the table describes the current status of each individual
under follow-up on 1 January each year (based on the last available measurement for that individual prior to the start of the year)
Individuals under follow-up on 1 January of year:
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
N 3,508 20,868 22,816 25,694 27,148 28,526 29,570 30,549 31,832 35,146 34,438 32,662 31,112
Male (%) 79.8 75.2 75.5 74.7 74.1 73.3 73.0 72.8 73.1 73.2 73.5 73.5 73.6
Age (years) Median 39 39 40 41 42 43 44 45 46 47 48 49 50
Previous AIDS (%) 25.9 25.8 26.3 26.3 26.6 26.7 26.8 27.1 26.9 26.5 26.9 27.5 27.8
10-year CVD risk (%) Low 5.1 35.7 42.3 45.4 49.5 52.8 57.0 61.9 64.2 63.9 66.8 69.8 71.7
Moderate 1.7 7.8 9.1 8.8 9.1 9.3 9.1 9.2 9.9 10.5 10.7 11.0 11.3
High 2.8 4.6 5.3 5.1 5.2 5.1 4.8 4.9 5.3 5.4 5.6 5.8 6.0
Unknown 90.7 51.9 43.4 40.7 36.2 32.8 29.2 24.0 20.7 20.2 16.9 13.4 11.1
Smoking statusa Current smoker 27.2 49.2 49.6 49.0 47.2 47.5 45.5 45.0 44.1 43.8 42.7 41.0 39.8
Ex-smoker 50.6 21.4 21.8 20.8 22.2 22.4 24.7 25.3 26.1 26.1 27.5 29.3 30.6
Never smoked 22.3 29.4 28.6 30.2 30.6 30.0 29.8 29.7 29.8 30.1 29.9 29.7 29.6
Family history of CVD (%) 5.1 8.7 8.7 8.3 8.2 8.1 8.0 8.0 7.7 7.3 7.5 7.7 7.8
Diabetes (%) 3.6 3.9 4.5 4.7 5.1 5.0 5.0 5.0 5.1 5.2 5.6 5.9 6.3
TC (mmol/L) Median 5.1 5.1 5.1 5.0 5.0 4.9 4.9 4.8 4.8 4.9 4.9 4.9 5.0
HDL-C (mmol/L) Median 1.1 1.1 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2
TG (mmol/L) Median 1.9 1.7 1.7 1.7 1.7 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.5
CD4 (cells/mm3) Median 380 448 461 465 460 460 468 480 494 503 527 548 566
Viral load (log10 copies/ml) Median 2.4 2.1 1.9 1.8 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7
aExpressed as a proportion of those with known smoking status, which has increased from 71.9 % of the cohort in 2000 to 89.5 % in 2012. CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, TC
total cholesterol, TG triglycerides
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Table 2 Association between 10-year CVD risk and i) initiations or ii) discontinuations of ABC in the pre- and post-March 2008
periods (factors included in adjusted analyses are listed in the Methods section)
Framingham risk group ABC initiations/total ART initiations Percentage (95 % CI) aOR (95 % CI)
i) Initiations of ABC
Pre-March 2008
Low/unknown 1,251/9,213 13.6 (12.8, 14.3) 1
Moderate/high 111/648 17.1 (13.9, 20.3) 1.14 (0.90, 1.44)
Post-March 2008
Low/unknown 326/4,282 7.6 (6.8, 8.4) 1
Moderate/high 33/622 5.3 (3.5, 7.1) 0.74 (0.48, 1.13)
Interaction P value 0.007
ii) Discontinuations of ABC Discontinuations/PYRS Rate/100 PYRS (95 % CI) aRR (95 % CI)
Suppressed/low viral load
Pre-March 2008
Low/unknown 2,045/16,506 12.4 (11.9, 12.9) 1
Moderate/high 562/5,465 10.3 (9.4, 11.1) 1.04 (0.93, 1.16)
Post-March 2008
Low/unknown 1,403/13,950 10.1 (9.5, 10.6) 1
Moderate/high 880/6,560 13.4 (12.5, 14.3) 1.49 (1.34, 1.65)
Interaction P value 0.0001
Non-suppressed viral load
Pre-March 2008
Low/unknown 2,966/7,766 38.2 (36.8, 39.6) 1
Moderate/high 662/2,041 32.4 (29.9, 34.9) 0.99 (0.90, 1.09)
Post-March 2008
Low/unknown 622/2,297 27.1 (25.0, 29.2) 1
Moderate/high 236/921 25.6 (22.4, 28.9) 1.23 (1.02, 1.48)
Interaction P value 0.07
ABC abacavir, aOR adjusted odds ratio, aRR adjusted rate ratio, ART antiretroviral therapy, CI confidence interval, CVD cardiovascular disease, PYRS person-years
Fig. 1 Changes to the use of ABC in the D:A:D cohort over time, overall and among groups stratified by CVD risk
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similar discontinuation rate to those with moderate or
high CVD risk (aRR 0.99 [0.90–1.09]), in the post-March
2008 era, those with moderate or high CVD risk were
23 % more likely to discontinue ABC than those with
low or unknown risk (aRR 1.23 [1.02–1.48], P value for
interaction = 0.07).
Association between current use of ABC and MI risk
By 1 February 2013, 941 MI events had occurred in the
cohort (rate 0.26 [95 % CI 0.24–0.27]/100 PYRS). Over-
all, the rate of MI was 0.47 [0.42–0.52]/100 PYRS among
those currently receiving ABC and 0.21 [0.19–0.22]/100
PYRS among those not currently receiving ABC. After
adjustment for potential confounders, current ABC use
was associated with a 98 % increase in MI rate (aRR 1.98
[1.72–2.29]), with no difference in the pre- (1.97 [1.68–
2.33]) and post- (1.97 [1.43–2.72]) March 2008 periods
(P value for interaction = 0.74) (Table 3).
Sensitivity analyses
Results were unchanged after stratifying by Framingham
risk group, or after further adjusting for factors poten-
tially on the causal pathway, including renal function,
dyslipidaemia and hypertension (Table 4).
Discussion
It is clear that there has been some reduction in the use
of ABC among those at higher risk of CVD in the more
recent period. In particular, since March 2008 individ-
uals at moderate or high CVD risk have been somewhat
less likely to initiate ABC as part of first-line ART regi-
mens, and more likely to discontinue ABC compared to
their counterparts with low or unknown underlying
CVD risk. Despite this reduction in the use of ABC in
higher risk persons, we continue to observe a strong
association between current ABC use and MI risk. This
association remains unchanged, even after adjustment
for the majority of known risk factors for CVD that may
have influenced the choice of NRTI within this popula-
tion. While it is not possible to adjust for unmeasured
confounders, the reduction in the use of ABC among in-
dividuals with high measured CVD risk is likely also to
have occurred in individuals with observed but unmeas-
ured high CVD risk. This strongly suggests that our
finding of a raised risk of MI for people on ABC is not
explained by channelling of people with high CVD risk
onto the drug. These results are of particular importance
at a time when the use of ABC, as part of a new single
tablet regimen, is likely to increase within many settings.
The clinical relevance of our findings will always be
dependent on the underlying risk of the event in a given
individual. However, the relative rate that we see is simi-
lar even in those at high CVD risk, raising particular
concerns about the use of ABC in this group.
Since the original publication from the D:A:D Study
Group in 2008 [2], several research groups have
attempted to replicate the findings from the study; the
findings from these studies have been reviewed in detail
in several recent review articles [28, 29]. The strongest
associations with ABC have, arguably, come from obser-
vational cohort studies. In 2008, the combined SMART/
INSIGHT and D:A:D study groups reported findings
based on the subgroup of patients who had been rando-
mised to receive continuous ART in the SMART trial
[3]; current use of ABC was associated with an excess
risk of clinical MI and major CVD events, both when a
strict and expanded definition for CVD was considered.
Three studies from the US Department of Veterans
Affairs (VA) Clinical Case Registries investigated the
association. In the study from Bedimo et al. [14], ABC-
containing cART was associated with a 27 % increase in
the risk of MI; this association was reduced, although
remained raised, after controlling for markers of chronic
kidney disease (adjusted rate ratio 1.23) and for known
Table 3 Results from multivariable Poisson regression models of association between current receipt of ABC and MI rate, overall and
stratified by calendar period. Factors included in adjusted analyses are listed in the Methods section
MI/PYRS Rate (95 % CI)/100 PYRS aRR (95 % CI)
Overall
Not currently on ABC 600/295,642 0.20 (0.19, 0.22) 1
Currently on ABC 341/71,917 0.47 (0.42, 0.52) 1.98 (1.72, 2.29)
Pre-March 2008
Not currently on ABC 425/169,417 0.25 (0.23, 0.28) 1
Currently on ABC 247/40,833 0.61 (0.53, 0.68) 1.97 (1.68, 2.33)
Post-March 2008
Not currently on ABC 175/126,225 0.14 (0.12, 0.16) 1
Currently on ABC 94/31,084 0.30 (0.24, 0.36) 1.97 (1.43, 2.72)
Interaction P value 0.74
ABC abacavir, aRR adjusted rate ratio, CI confidence interval, MI myocardial infarction, PYRS person-years
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risk factors for MI (1.18). In an updated analysis of the
same dataset [7], use of ABC was significantly associated
with several outcomes, including atherosclerotic CVD
events, coronary disease and cerebrovascular disease,
with non-significant raised risk also seen for heart fail-
ure. Finally, Desai et al. reported a significant odds ratio
of 1.50 for current abacavir exposure in a study pub-
lished in 2015 [30]. The risk of hospitalisation with MI
among participants in the Danish HIV cohort study [5]
was doubled in ABC users compared with non-ABC
users. In contrast, no association was seen between MI
risk and ABC use in 6,517 patients receiving HIV care at
one of two hospitals in Boston [10]. More recently,
Marcus et al. [31] reported that ABC users in the Kaiser
Permanente Northern and Southern California cohort
had a 2.2-fold higher risk of CVD compared with pa-
tients initiating regimens without ABC.
Several case-control studies have been conducted to
investigate the association. In the French Hospital’s
Database on HIV [13], 289 individuals with a first defin-
ite/probable MI occurring between 2000 and 2006 were
each matched to up to five control individuals with no
history of MI. Whilst recent and past ABC use in this
study was more likely to be seen in cases than in con-
trols, these associations were marginally non-significant.
In Montreal [6], Durand et al. reported that increased
recent exposure to ABC, didanosine (ddI), stavudine
(d4T) and zalcitabine (ddC) was found in cases with MI
compared to controls without MI.
One of the limitations of observational studies is the
potential presence of confounding. As patients are not
randomised to the choice of therapy, the characteristics
of those starting different drugs are likely to differ, and
this may introduce bias if these characteristics are also
associated with CVD risk. Due to the randomisation
process employed, randomised controlled trials (RCTs)
are generally thought to be free of confounding and, as
such, provide a high-level of evidence to support a
causal association. In the STEAL trial [4], serious non-
AIDS events (including CVD) and ischaemic CVD both
occurred significantly less frequently in individuals ran-
domised to tenofovir/emtricitabine compared to those
randomised to ABC/lamivudine. The trial was, however,
a small one and had not been powered to detect a differ-
ence in these secondary endpoints.
Several meta-analyses of randomised trials have also
been performed [11, 12, 15, 16] and have failed to dem-
onstrate an association between ABC use and MI risk.
Results from these meta-analyses must be interpreted,
however, in the context of a population of largely ART-
naïve individuals who are generally healthier and at
lower CVD risk (due to trial inclusion/exclusion criteria,
particularly relating to age restrictions and the presence
of co-morbidities) than the wider HIV population. Many
of the trials included in these meta-analyses were con-
ducted at a time when associations with CVD had not yet
been recognised, and MI and CVD were not captured as
pre-specified endpoints. The under-ascertainment of
events that may result, combined with an already low
underlying event rate, is likely to contribute to the lack of
associations seen in these meta-analyses. Of note, a recent
study that attempted to emulate a RCT using data from a
North Carolina Medicaid dataset, did report an increased
rate of MI among patients initiating ABC compared with
tenofovir [32]. A recent meta-analysis of observational
studies [29] also reported an association between use of
ABC and MI risk, although the pooled estimates were
based on only the D:A:D [2] and Danish [5] studies.
One of the reasons for the continued debate about the
potential association between ABC and MI is that there
is no confirmed biological mechanism for the associ-
ation. The MI signal associated with use of ABC is
maintained as long as the drug is continued (i.e. over
many years), eliminating the possibility that this is an ad-
verse effect related to the well-known hypersensitivity
reaction that may present early after drug initiation in
persons with a HLA-B*5701 haplotype. Nevertheless, as
the mechanism for the hypersensitivity reaction develops
when the drug is presented by the HLA system to T-
lymphocytes, it is possible that other HLA haplotypes
Table 4 Results from sensitivity analyses. i) Adjusted rate ratio for the association between MI and ABC, stratified by calendar period
and CVD risk, and ii) adjusted rate ratio for the association between MI and ABC after further adjustment for factors that potentially
lie on the causal pathway (see Methods section)
Pre-March 2008 Post-March 2008 P value (interaction
between ABC use and
calendar period)
Sensitivity analysis MI event rate
(95 % CI)/100 PYRS
aRR (95 % CI) MI event rate
(95 % CI)/100 PYRS
aRR (95 % CI)
i) Stratified by Framingham risk
Low 0.14 (0.12, 0.16) 2.48 (1.74, 3.52) 0.08 (0.06, 0.09) 2.11 (1.12, 3.98) 0.78
Moderate 0.69 (0.59, 0.80) 1.69 (1.21, 2.35) 0.32 (0.26, 0.39) 2.19 (1.25, 3.84) 0.68
High 1.80 (1.56, 2.05) 1.51(1.12, 2.05) 0.74 (0.58, 0.90) 1.65 (0.93, 2.92) 0.16
ii) Further adjustment for factors
on causal pathway
n/a 1.88 (1.55, 2.28) n/a 2.03 (1.46, 2.84) 0.61
ABC abacavir, aRR adjusted rate ratio, CI confidence interval, CVD cardiovascular disease, MI myocardial infarction
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may also convey a similar risk but without a distinct
clinical phenotype. This possibility was supported by
early cross-sectional analyses of the SMART trial [3],
which suggested that baseline levels of high sensitivity
C-reactive protein (hs-CRP) and IL-6 at baseline were
higher in those receiving ABC than in those receiving
other NRTIs. Subsequent analyses of follow-up informa-
tion from the STEAL study [33] and other (generally
small) studies [34–36] provided an inconsistent picture,
with associations reported in some studies [37–39] but
not others [40–45]. Recently, in vitro and in vivo animal
experiments have demonstrated the ability of ABC to in-
duce inflammation of the vascular wall by enhancing
leucocyte attachment to endothelial cells through en-
hanced expression and/or function of the macrophage-1
antigen [46–48]. A recent study from Papakonstantinou
et al. [49] demonstrated an increased level of platelet ac-
tivating factor (PAF), a potent inflammatory factor, at
3 months after individuals started ABC suggesting a link
between ABC use and MI risk. The possibility of a dif-
ferent underlying mechanism for the development of
atherosclerosis and CVD in treated and untreated indi-
viduals [50] may explain differences in outcomes be-
tween studies of ART- naïve individuals starting cART
for the first time (as is commonly the case in rando-
mised trials), and those who are on established treat-
ment (as is more often the case in observational studies).
ABC use has been shown to impair endothelial function
[39]. Unfortunately, no measurements of endothelial func-
tion are currently available from randomised trials that
compare virologically suppressive regimens of ABC versus
non-ABC-containing regimens. The mechanisms that ex-
plain this observation also remain to be elucidated, but
the studies that suggest that ABC causes vascular endo-
thelial inflammation may hint at one possibility [46–48].
Conversely, ABC is not known to affect lipid or glucose
metabolism nor accelerate subclinical atherosclerosis. This
is in contrast to the HIV protease inhibitors, which likely
accelerate CVD risk by perturbing lipid metabolism gener-
ally and, in particular, in macrophages involved in plaque
formation.
Arguably, the most promising potential mechanism to
date relates to the ability of ABC to lead to platelet re-
activity [17, 18]. The metabolite of ABC, carbovir triphos-
phate, is a competitive inhibitor of the guanylyl cyclase
enzyme in platelets [18], and this inhibition lowers the
cyclic guanosine monophosphate (cGMP) concentration
resulting in platelets that are more reactive. An association
with hyperreactive platelets, with their short lifespan,
would be consistent with the reversible nature of the ABC
association with MI, and with the findings related to in-
creased expression of PAF in the first few months on ABC
[49, 51]. In support of this, Falcinelli et al. [19] reported
findings suggesting that treatment with ABC enhances
in vivo platelet activation and induces platelet hyperreac-
tivity by blunting the inhibitory effects of nitric oxide on
platelets. Seemingly in contrast to these findings, a recent
Danish study [52] found evidence of reduced platelet
aggregation and clot initiation in both treated and un-
treated HIV-positive individuals. However, the authors did
not state how many patients in the treated group were re-
ceiving ABC, nor did they consider any specific drug
associations.
Clearly, confounding cannot be ruled out in any co-
hort study. Although our initial report provided several
arguments against confounding as an explanation, this
concern continued to be levelled against the study. In
particular, there has been a frequently raised concern
that channelling by renal function (whereby those with
poorer renal function would be preferentially placed on
ABC-containing regimens to avoid use of tenofovir, a
drug that has well-known renal toxicities) might induce
an artificial association with MI, due to the known cor-
relation between renal function and CVD risk. This was
first raised by Bedimo and colleagues [14] who reported
that after adjustment for renal function the P value for
the association between MI and ABC use changed from
0.06 to 0.11. However, it is noteworthy that the hazard
ratio itself was reduced only slightly from 1.27 to 1.23,
indicative of only a modest confounding effect of renal
function. The later study from the VA group did include
adjustment for renal function, both at baseline and over
follow-up [7] with no attenuation of association; Marcus
et al. [31] also confirmed that their association was inde-
pendent of renal function. Further, in an updated ana-
lysis from the D:A:D group [21] (as well as in the
present analysis), the reported association with ABC was
unchanged after adjustment for various measures of
renal function. Confounding by recreational drug use
has also been proposed as a possible explanation for the
findings [13], although the VA analysis [7] did also in-
clude adjustment for this factor and clinicians within the
D:A:D study reported that this information, if available,
would be unlikely to influence choice of cART. Most
importantly, we consider that, the fact that the reported
association between MI and ABC is unchanged, provides
the strongest evidence against channelling bias as an
explanation for our findings.
One concern in analyses such as this is the possibility
of time-varying confounding. If factors that are associ-
ated with the initiation of ABC also lie on the causal
pathway between the use of abacavir and MI risk, then
adjustment for these factors in standard multivariable
analyses will generally result in biased estimates of the
relative risk. For this reason, we did not include such
factors in our primary analysis. However, the fact that
the relative risk associated with current abacavir use was
virtually unchanged in our sensitivity analyses which did
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include factors thought to be potentially on the causal
pathway suggests that little time-varying confounding
exists with these factors. This is also supported by the
mechanistic studies which suggest a very different path-
way for the association seen.
Conclusion
In conclusion, there has been some channelling of ABC
away from those at higher risk of CVD since 2008 when
this safety signal was first identified. Despite this, we
continue to observe a strong association between
current ABC use and MI risk. The signal is furthermore
supported by some, but not all, other observational stud-
ies, whereas meta-analyses of previous RCTs of ABC do
not support an association among low CVD risk popula-
tions. Outside of the HIV field there have been well-
documented examples of reported safety signals from
observational studies that have failed to be confirmed in
large-scale randomised trials (for example, [53]). How-
ever, in these cases, there is rarely an evidence-based
biological mechanism for the associations seen. The clin-
ical relevance of the ABC signal with CVD has been
explored by basic science studies that suggest several po-
tential biological mechanisms to explain the association.
Despite these advances, a suitably powered RCT able to
provide definitive evidence on the safety of ABC in
patients with elevated underlying CVD risk has not been
undertaken and it is questionable, given this further ana-
lysis of the D:A:D study, whether such a trial would be
deemed to be ethical. Unfortunately, the inconsistent
findings from the studies, together with few attempts to
generate evidence of better quality, leaves patients with
HIV and their treating physicians with continued ambi-
guity as to the safety of using ABC in patients with
elevated risk of CVD. We call for action to address
this ambiguity, with a greater focus on mechanistic
studies which may lead to greater insight into such
an association.
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S. Delveaux, F. Diarra, C. D’Ivernois, A. Frosch, S. Geffard, C. Hannapier, S.
Lawson-Ayayi, E. Lenaud, O. Leleux, F. Le Marec, J. Leray, I. Louis, G. Palmer, A.
Pougetoux, X. Sicard, D. Touchard and B. Uwamaliya-Nziyumvira.
3. Australian HIV Observational Database (AHOD), Australia
Central coordination: M. Law1, K. Petoumenos, H. McManus, S. Wright and C.
Bendall (Sydney, New South Wales).
Participating physicians: R. Moore, S. Edwards, J. Hoy, K. Watson, N. Roth, J.
Nicholson (Melbourne, Victoria); M. Bloch, T. Franic, D. Baker, R. Vale, A. Carr,
D. Cooper (Sydney, New South Wales); J. Chuah, M. Ngieng (Gold Coast,
Queensland); D. Nolan and J. Skett (Perth, Western Australia).
4. Barcelona Antiretroviral Surveillance Study (BASS), Spain
Central coordination: G. Calvo1, F. Torres and S. Mateu (Barcelona).
Participating physicians: P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J.
Cadafalch, M. Fuster (Barcelona); C. Codina, G. Sirera and A. Vaqué (Badalona).
5. The Brussels St. Pierre Cohort, Belgium
Coordination: S. De Wit1, N. Clumeck, M. Delforge and C. Necsoi.
Participating physicians: N. Clumeck, S. De Wit1, A.F. Gennotte, M. Gerard, K.
Kabeya, D. Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille and Y. Van
Laethem.
6. Terry Beirn Community Programs for Clinical Research on AIDS
(CPCRA), USA
Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr1, E. Krum, G.
Thompson and D. Wentworth.
Participating physicians: R. Luskin-Hawk (Chicago, IL); E. Telzak (Bronx, NY);
W.M. El-Sadr (Harlem, NY); D.I. Abrams (San Francisco, CA); D. Cohn (Denver,
CO); N. Markowitz (Detroit, MI); R. Arduino (Houston, TX); D. Mushatt (New
Orleans, LA); G. Friedland (New Haven, CT); G. Perez (Newark, NJ); E. Tedaldi
(Philadelphia, PA); E. Fisher (Richmond, VA); F. Gordin (Washington, DC); L.R.
Crane (Detroit, MI); J. Sampson (Portland, OR); and J. Baxter (Camden, NJ).
7. EuroSIDA, multinational
Coordinating centre: J. Lundgren1,2, O. Kirk1, A. Mocroft, A. Cozzi-Lepri, D.
Grint, D. Podlekareva, J. Kjær, L. Peters, J. Reekie, J. Kowalska, J. Tverland, A.H.
Fischer and J. Nielsen.
Participating countries and physicians:
Argentina: (M. Losso), C. Elias, Hospital JM Ramos Mejia, Buenos Aires.
Austria: (N. Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; and R.
Zangerle, Medical University Innsbruck, Innsbruck.
Belarus: (I. Karpov), A. Vassilenko, Belarus State Medical University, Minsk; V.M.
Mitsura, Gomel State Medical University, Gomel; and O. Suetnov, Regional
AIDS Centre, Svetlogorsk.
Belgium: (N. Clumeck), S. De Wit1 and M. Delforge, Saint-Pierre Hospital,
Brussels; R. Colebunders, Institute of Tropical Medicine, Antwerp; and L.
Vandekerckhove, University Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V. Hadziosmanovic), Klinicki Centar Univerziteta
Sarajevo, Sarajevo.
Bulgaria: (K. Kostov), Infectious Diseases Hospital, Sofia.
Croatia: (J. Begovac), University Hospital of Infectious Diseases, Zagreb.
Czech Republic: (L. Machala), D. Jilich, Faculty Hospital Bulovka, Prague; and
D. Sedlacek, Charles University Hospital, Plzen.
Denmark: (J. Nielsen), G. Kronborg, T. Benfield and M. Larsen, Hvidovre Hospital,
Copenhagen; J. Gerstoft, T. Katzenstein, A.B.E. Hansen and P. Skinhøj,
Rigshospitalet, Copenhagen; C. Pedersen, Odense University Hospital, Odense;
and L. Ostergaard, Skejby Hospital, Aarhus.
Estonia: (K. Zilmer), West-Tallinn Central Hospital, xTallinn; and J. Smidt, Nak-
kusosakond Siseklinik, Kohtla-Järve.
Finland: (M. Ristola), Helsinki University Central Hospital, Helsinki.
France: (C. Katlama), Hôpital de la Pitié-Salpétière, Paris; J.P. Viard, Hôpital
Necker-Enfants Malades, Paris; P.M. Girard, Hospital Saint-Antoine, Paris; J.M.
Livrozet, Hôpital Edouard Herriot, Lyon; P. Vanhems, University Claude Ber-
nard, Lyon; C. Pradier, Hôpital de l’Archet, Nice; and F. Dabis1 and D. Neau,
Unité INSERM, Bordeaux.
Germany: (J. Rockstroh), Universitäts Klinik Bonn; R. Schmidt, Medizinische
Hochschule Hannover; J. van Lunzen and O. Degen, University Medical
Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; H.J. Stellbrink,
IPM Study Center, Hamburg; S. Staszewski, J.W. Goethe University Hospital,
Frankfurt; M. Bickel, Medizinische Poliklinik, Munich; and G. Fätkenheuer,
Universität Köln, Cologne.
Greece: (J. Kosmidis), P. Gargalianos, G. Xylomenos and J. Perdios, Athens
General Hospital, Athens; G. Panos, A. Filandras and E. Karabatsaki, 1st IKA
Hospital, Athens; and H. Sambatakou, Ippokration Genereal Hospital, Athens.
Hungary: (D. Banhegyi), Szent Lásló Hospital, Budapest.
Ireland: (F. Mulcahy), St. James’s Hospital, Dublin.
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Israel: (I. Yust), D. Turner and M. Burke, Ichilov Hospital, Tel Aviv; S. Pollack
and G. Hassoun, Rambam Medical Center, Haifa; and S. Maayan, Hadassah
University Hospital, Jerusalem.
Italy: (S. Vella), Istituto Superiore di Sanità, Rome; R. Esposito, I. Mazeu and C.
Mussini, Università Modena, Modena; C. Arici, Ospedale Riuniti, Bergamo; R.
Pristera, Ospedale Generale Regionale, Bolzano; F. Mazzotta, A. Gabbuti,
Ospedale Santa Maria Annunziata, Firenze; V. Vullo and M. Lichtner, University di
Roma la Sapienza, Rome; A. Chirianni, E. Montesarchio and M. Gargiulo, Presidio
Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G. Antonucci, A. Testa, P.
Narciso, C. Vlassi and M. Zaccarelli, Istituto Nazionale Malattie Infettive Lazzaro
Spallanzani, Rome; A. Lazzarin, A. Castagna and N. Gianotti, Ospedale San
Raffaele, Milan; M. Galli and A. Ridolfo, Ospedale Luigi Sacco, Milan; and A.
d’Arminio Monforte, Istituto Di Clinica Malattie Infettive e Tropicale, Milan.
Latvia: (B. Rozentale), I. Zeltina, Infectology Centre of Latvia, Riga.
Lithuania: (S. Chaplinskas), Lithuanian AIDS Centre, Vilnius.
Luxembourg: (R. Hemmer), T. Staub, Centre Hospitalier, Luxembourg.
Netherlands: (P. Reiss1), Academisch Medisch Centrum bij de Universiteit van
Amsterdam, Amsterdam.
Norway: (V. Ormaasen), A. Maeland and J. Bruun, Ullevål Hospital, Oslo.
Poland: (B. Knysz), J. Gasiorowski, Medical University, Wroclaw; A. Horban and
E. Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; A. Grzeszczuk and
R. Flisiak, Medical University, Bialystok; A. Boron-Kaczmarska, M. Pynka and M.
Parczewski, Medical University, Szczecin; M. Beniowski and E. Mularska,
Osrodek Diagnostyki i Terapii AIDS, Chorzow; H. Trocha, Medical University,
Gdansk; and E. Jablonowska, E. Malolepsza and K. Wojcik, Wojewodzki Szpital
Specjalistyczny, Lodz.
Portugal: (F. Antunes), M. Doroana and L. Caldeira, Hospital Santa Maria,
Lisbon; K. Mansinho, Hospital de Egas Moniz, Lisbon; and F. Maltez, Hospital
Curry Cabral, Lisbon.
Romania: (D. Duiculescu), Spitalul Clinic de Boli Infectioase si Tropicale “Dr.
Victor Babes”, Bucuresti.
Russia: (A. Rakhmanova), Medical Academy Botkin Hospital, St. Petersburg; N.
Zakharova, St. Petersburg AIDS Centre, St. Peterburg; and S. Buzunova,
Novgorod Centre for AIDS, Novgorod.
Serbia: (D. Jevtovic), Institute for Infectious and Tropical Diseases, Belgrade.
Slovakia: (M. Mokráš), D. Staneková, Dérer Hospital, Bratislava.
Slovenia: (J. Tomazic), University Clinical Centre Ljubljana, Ljubljana.
Spain: (J. González-Lahoz), V. Soriano, P. Labarga and J. Medrano, Hospital
Carlos III, Madrid; S. Moreno and J.M. Rodriguez, Hospital Ramon y Cajal,
Madrid; B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig and I. Bravo, Hospital
Germans Trias i Pujol, Badalona; J.M. Gatell and J.M. Miró, Hospital Clinic i
Provincial, Barcelona; and P. Domingo, M. Gutierrez, G. Mateo and M.A.
Sambeat, Hospital Sant Pau, Barcelona.
Sweden: (A. Karlsson), Venhaelsan-Sodersjukhuset, Stockholm; and L. Flam-
holc, Malmö University Hospital, Malmö.
Switzerland: (B. Ledergerber), R. Weber1, University Hospital, Zürich; P.
Francioli and M. Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne;
B. Hirschel and E. Boffi, Hospital Cantonal Universitaire de Geneve, Geneva; H.
Furrer, Inselspital Bern, Bern; and M. Battegay and L. Elzi, University Hospital
Basel, Basel.
Ukraine: (E. Kravchenko), N. Chentsova, Kiev Centre for AIDS, Kiev; V. Frolov
and G. Kutsyna, Luhansk State Medical University; Luhansk; S. Servitskiy,
Odessa Region AIDS Center, Odessa; and M. Krasnov, Kharkov State Medical
University, Kharkov.
United Kingdom: (S. Barton), John Hunter Clinic, Chelsea and Westminster
Hospital, London; A.M. Johnson and D. Mercey, Royal Free and University
College London Medical School, London (University College Campus); A.
Phillips, M.A. Johnson and A. Mocroft, Royal Free and University College
London Medical School, London (Royal Free Campus); M. Murphy, Medical
College of St. Bartholomew’s Hospital, London; J. Weber and G. Scullard,
Faculty of Medicine at Imperial College London, St. Mary’s Hospital, London;
M. Fisher, Royal Sussex County Hospital, Brighton; and C. Leen, Western
General Hospital, Edinburgh.
8. HivBivus, Sweden
Central coordination: L. Morfeldt1, G. Thulin and A. Sundström.
Participating physicians: B. Åkerlund (Huddinge); K. Koppel, A. Karlsson
(Stockholm); L. Flamholc and C. Håkangård (Malmö).
9. The ICONA Foundation, Italy
Board of directors: M. Moroni (chair), G. Angarano, A. Antinori, O.
Armignacco, A. d’Arminio Monforte1, F. Castelli, R. Cauda, G. Di Perri, M. Galli,
R. Iardino, G. Ippolito, A. Lazzarin, C.F. Perno, F. von Schloesser and P. Viale.
Scientific secretary: A d’Arminio Monforte1, A. Antinori, A. Castagna, F.
Ceccherini-Silberstein, A. Cozzi-Lepri, E. Girardi, S. Lo Caputo, C. Mussini and
M. Puoti.
ICONA Steering Committee: M. Andreoni, A. Ammassari, A. Antinori, A.
d’Arminio Monforte, C. Balotta, P. Bonfanti, S. Bonora, M. Borderi, R. Capobianchi,
A. Castagna, F. Ceccherini-Silberstein, A. Cingolani, P. Cinque, A. Cozzi-Lepri, A. De
Luca, A. Di Biagio, E. Girardi, N. Gianotti, A. Gori, G. Guaraldi, G. Lapadula, M.
Lichtner, S. Lo Caputo, G. Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L.
Monno, C. Mussini, M. Puoti, E. Quiros Roldan and S. Rusconi.
Statistical and monitoring team: A.Cozzi-Lepri, P. Cicconi, I. Fanti, T.
Formenti, L. Galli and P. Lorenzini.
Participating physicians: A. Giacometti, A. Costantini (Ancona); G. Angarano,
L. Monno, C. Santoro (Bari); F. Maggiolo, C. Suardi (Bergamo); P. Viale, E.
Vanino, G. Verucchi (Bologna); F. Castelli, E. Quiros Roldan, C. Minardi
(Brescia); T. Quirino, C. Abeli (Busto Arsizio); P.E. Manconi, P. Piano (Cagliari); J.
Vecchiet, K. Falasca (Chieti); L. Sighinolfi, D. Segala (Ferrara); F. Mazzotta, S. Lo
Caputo (Firenze); G. Cassola, G. Viscoli, A. Alessandrini, R. Piscopo, G. Mazzarello
(Genova); C. Mastroianni, V. Belvisi (Latina); P. Bonfanti, I. Caramma (Lecco); A.P.
Castelli (Macerata); M. Galli, A. Lazzarin, G. Rizzardini, M. Puoti, A. d’Arminio
Monforte, A.L. Ridolfo, R. Piolini, A. Castagna, S. Salpietro, L. Carenzi, M.C. Moioli, P.
Cicconi, G. Marchetti (Milano); C. Mussini, C. Puzzolante (Modena); A. Gori, G.
Lapadula (Monza); N. Abrescia, A. Chirianni, M.G. Guida, M. Onofrio (Napoli); F.
Baldelli, D. Francisci (Perugia); G. Parruti, T. Ursini (Pescara); G. Magnani, M.A. Ursitti
(Reggio Emilia); R. Cauda, M. Andreoni, A. Antinori, V. Vullo, A. Cingolani, A. d’Avino,
A. Ammassari, L. Gallo, E. Nicastri, R. Acinapura, M. Capozzi, R. Libertone, G. Tebano
(Roma); A. Cattelan (Rovigo); M.S. Mura, G. Madeddu (Sassari); P. Caramello, G. Di
Perri, G.C. Orofino, S. Bonora, M. Sciandra (Torino); G. Pellizzer and V. Manfrin
(Vicenza).
10. Nice HIV Cohort, France
Central coordination: C. Pradier1, E. Fontas and C. Caissotti.
Participating physicians: P. Dellamonica, E. Bernard, E. Cua, F. De Salvador-
Guillouet, J. Durant, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost, B.
Prouvost-Keller, S. Pillet, P. Pugliese, V. Rahelinirina and P.M. Roger.
Clinical research assistant: K. Dollet.
11. Swiss HIV Cohort Study (SHCS), Switzerland
Participating physicians: V. Aubert, M. Battegay, E. Bernasconi, J. Böni, H.C.
Bucher, C. Burton-Jeangros, A. Calmy, M. Cavassini, G. Dollenmaier, M. Egger,
L. Elzi, J. Fehr, J. Fellay, H. Furrer (Chairman of the Clinical and Laboratory
Committee), C.A. Fux, M. Gorgievski, H. Günthard (President of the SHCS), D.
Haerry (Deputy of “Positive Council”), B. Hasse, H.H. Hirsch, M. Hoffmann, I.
Hösli, C. Kahlert, L. Kaiser, O. Keiser, T. Klimkait, R. Kouyos, H. Kovari, B.
Ledergerber, G. Martinetti, B. Martinez de Tejada, K. Metzner, N. Müller, D.
Nadal, D. Nicca, G. Pantaleo, A. Rauch (Chairman of the Scientific Board), S.
Regenass, M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the
Mother and Child Substudy), F. Schöni-Affolter, P. Schmid, J. Schüpbach, R.
Speck, P. Tarr, A. Telenti, A. Trkola, P. Vernazza, R. Weber1 and S. Yerly.
The data are gathered by five Swiss university hospitals, two cantonal
hospitals, 15 affiliated hospitals and 36 private physicians (listed in http://
www.shcs.ch/180-health-care-providers).
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